Literature DB >> 9066350

Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome.

.   

Abstract

Plasma exchange (PE) is the standard treatment in Guillain-Barré syndrome (GBS) patients who have lost the ability to walk. The effect of exchanges before this stage and the optimal number of exchanges for the other patients are still unknown. We randomized 556 GBS patients according to severity and number of exchanges as follows: Zero versus 2 PEs for patients who could walk-with or without aid-but not run, or who could stand up unaided (mild group); 2 versus 4 PEs for patients who could not stand up unaided (moderate group); and 4 versus 6 PEs for mechanically ventilated patients (severe group). In the mild group, 2 PEs were more effective than none for time to onset of motor recovery (median, 4 vs 8 days, respectively). In the moderate group, 4 PEs were more beneficial than 2 for time to walk with assistance (median, 20 vs 24 days) and for 1-year full muscle-strength recovery rate (64% vs 46%). Six PEs were no more beneficial than 4 in the severe cases. Patients with mild GBS on admission should receive 2 PEs. Patients with moderate and severe forms should benefit from 2 further exchanges.

Entities:  

Mesh:

Year:  1997        PMID: 9066350     DOI: 10.1002/ana.410410304

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  41 in total

1.  Abstracts of the 13th Meeting of the European Neurological Society. 14-18 June 2003, Istanbul, Turkey.

Authors: 
Journal:  J Neurol       Date:  2003-05       Impact factor: 4.849

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 4.  [Plasma exchange as a therapeutic option in neurological disorders].

Authors:  H C Lehmann; H P Hartung; G R Hetzel; B C Kieseier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

5.  Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases.

Authors:  Anil Tombak; Mehmet Ali Uçar; Aydan Akdeniz; Arda Yilmaz; Hakan Kaleagası; Mehmet Ali Sungur; Eyup Naci Tiftik
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-22       Impact factor: 0.900

Review 6.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

Review 7.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

8.  Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barré syndrome.

Authors:  David Orlikowski; Tarek Sharshar; Raphael Porcher; Djillali Annane; Jean Claude Raphael; Bernard Clair
Journal:  Intensive Care Med       Date:  2006-09-21       Impact factor: 17.440

Review 9.  The Importance of Rare Subtypes in Diagnosis and Treatment of Peripheral Neuropathy: A Review.

Authors:  Brian C Callaghan; Raymond S Price; Kevin S Chen; Eva L Feldman
Journal:  JAMA Neurol       Date:  2015-12       Impact factor: 18.302

Review 10.  Respiratory dysfunction in Guillain-Barré Syndrome.

Authors:  David Orlikowski; Hélène Prigent; Tarek Sharshar; Frédéric Lofaso; Jean Claude Raphael
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.